|
1
|
Burus T, Damgacioglu H, Huang B, Christian
WJ, Hull PC, Ellis AR, Arnold SM, Deshmukh AA and Lang Kuhs KA:
Trends in oral tongue cancer incidence in the US. JAMA Otolaryngol
Head Neck Surg. 150:436–443. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mohideen K, Krithika C, Jeddy N, Bharathi
R, Thayumanavan B and Sankari SL: Meta-analysis on risk factors of
squamous cell carcinoma of the tongue in young adults. J Oral
Maxillofac Pathol. 23:450–457. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Walcher L, Kistenmacher AK, Suo H, Kitte
R, Dluczek S, Strauß A, Blaudszun AR, Yevsa T, Fricke S and
Kossatz-Boehlert U: Cancer stem cells-origins and biomarkers:
Perspectives for targeted personalized therapies. Front Immunol.
11:12802020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu F, Chen S, Ren S, Wang R, Tan Y, Chen
R, Li B, Cao H and Li J: Regulating lipid metabolism via
mitochondrial dynamics in tongue squamous cell carcinoma cancer
stem cells. Recent Pat Anticancer Drug Discov. 20:445–459. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hoseinian SN, Saeedi M, Saravani ME,
Zenoozi S, Mehranfar F and Pouyan A: Navigating the molecular
signaling: Deciphering cancer stem cell self-renewal pathways. Int
J Mol Cell Med. 14:735–776. 2025.PubMed/NCBI
|
|
6
|
Najafi M, Mortezaee K and Majidpoor J:
Cancer stem cell (CSC) resistance drivers. Life Sci.
234:1167812019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hoque S, Dhar R, Kar R, Mukherjee S,
Mukherjee D, Mukerjee N, Nag S, Tomar N and Mallik S: Cancer stem
cells (CSCs): Key player of radiotherapy resistance and its
clinical significance. Biomarkers. 28:139–151. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gholamzad A, Khakpour N, Khosroshahi EM,
Asadi S, Koohpar ZK, Matinahmadi A, Jebali A, Rashidi M, Hashemi M,
Sadi FH and Gholamzad M: Cancer stem cells: The important role of
CD markers, signaling pathways, and MicroRNAs. Pathol Res Pract.
256:1552272024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang K, Zhou XK, Wu M, Kang FW, Wang ZL
and Zhu Y: Role of CD133+ cells in tongue squamous
carcinomas: Characteristics of ‘stemness’ in vivo and in vitro.
Oncol Lett. 12:863–870. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sato T, Oshi M, Huang JL, Chida K, Roy AM,
Endo I and Takabe K: CD133 expression is associated with less DNA
repair, better response to chemotherapy and survival in
ER-positive/HER2-negative breast cancer. Res Sq [Preprint].
rs.3.rs-4148608. 2024.PubMed/NCBI
|
|
11
|
Kang FW, Wang K, Wu M, Wang ZL, Zhu Y and
Min R: Biological characteristics of CD133+ subpopulation in tongue
squamous cell carcinoma Tca8113 cell line. Hua Xi Kou Qiang Yi Xue
Za Zhi. 28:560–564. 2010.(In Chinese). PubMed/NCBI
|
|
12
|
Mascolo M, Ilardi G, Romano MF, Celetti A,
Siano M, Romano S, Luise C, Merolla F, Rocco A, Vecchione ML, et
al: Overexpression of chromatin assembly factor-1 p60,
poly(ADP-ribose) polymerase 1 and nestin predicts metastasizing
behaviour of oral cancer. Histopathology. 61:1089–1105. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vered M, Shnaiderman-Shapiro A,
Zlotogorski-Hurvitz A, Salo T and Yahalom R: Cancer-associated
fibroblasts in the tumor microenvironment of tongue carcinoma is a
heterogeneous cell population. Acta Histochem. 121:1514462019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun Y, Han J, Lu Y, Yang X and Fan M:
Biological characteristics of a cell subpopulation in tongue
squamous cell carcinoma. Oral Dis. 18:169–177. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Biserova K, Jakovlevs A, Uljanovs R and
Strumfa I: Cancer stem cells: Significance in origin, pathogenesis
and treatment of glioblastoma. Cells. 10:6202021. View Article : Google Scholar
|
|
16
|
Babaei G, Aziz SG and Jaghi NZZ: EMT,
cancer stem cells and autophagy; the three main axes of metastasis.
Biomed Pharmacother. 133:1109092021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chu X, Tian W, Ning J, Xiao G, Zhou Y,
Wang Z, Zhai Z, Tanzhu G, Yang J and Zhou R: Cancer stem cells:
Advances in knowledge and implications for cancer therapy. Signal
Transduct Target Ther. 9:1702024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Patil T, Rohiwal SS and Tiwari AP: Stem
cells: Therapeutic implications in chemotherapy and radiotherapy
resistance in cancer therapy. Curr Stem Cell Res Ther. 18:750–765.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Owusu-Akyaw A, Krishnamoorthy K, Goldsmith
LT and Morelli SS: The role of mesenchymal-epithelial transition in
endometrial function. Hum Reprod Update. 25:114–133. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bakir B, Chiarella AM, Pitarresi JR and
Rustgi AK: EMT, MET, plasticity, and tumor metastasis. Trends Cell
Biol. 30:764–776. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bayik D and Lathia JD: Cancer stem
cell-immune cell crosstalk in tumour progression. Nat Rev Cancer.
21:526–536. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen S, Du Y, Guan XY and Yan Q: The
current status of tumor microenvironment and cancer stem cells in
sorafenib resistance of hepatocellular carcinoma. Front Oncol.
13:12045132023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lei ZN, Teng QX, Koya J, Liu Y, Chen Z,
Zeng L, Chen ZS, Fang S, Wang J, Liu Y and Pan Y: The correlation
between cancer stem cells and epithelial-mesenchymal transition:
Molecular mechanisms and significance in cancer theragnosis. Front
Immunol. 15:14172012024. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Saw PE, Liu Q, Wong PP and Song E: Cancer
stem cell mimicry for immune evasion and therapeutic resistance.
Cell Stem Cell. 31:1101–1112. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Muñoz-Galván S, Verdugo-Sivianes EM,
Santos-Pereira JM, Estevez-García P and Carnero A: Essential role
of PLD2 in hypoxia-induced stemness and therapy resistance in
ovarian tumors. J Exp Clin Cancer Res. 43:572024. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li X, González-Maroto C and Tavassoli M:
Crosstalk between CAFs and tumour cells in head and neck cancer.
Cell Death Discov. 10:3032024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li J, Wang J, Xie D, Pei Q, Wan X, Xing HR
and Ye T: Characteristics of the PI3K/AKT and MAPK/ERK pathways
involved in the maintenance of self-renewal in lung cancer
stem-like cells. Int J Biol Sci. 17:1191–1202. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pang X, He X, Qiu Z, Zhang H, Xie R, Liu
Z, Gu Y, Zhao N, Xiang Q and Cui Y: Targeting integrin pathways:
Mechanisms and advances in therapy. Signal Transduct Target Ther.
8:12023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bierbaumer L, Katschnig AM, Radic-Sarikas
B, Kauer MO, Petro JA, Högler S, Gurnhofer E, Pedot G, Schäfer BW,
Schwentner R, et al: YAP/TAZ inhibition reduces metastatic
potential of Ewing sarcoma cells. Oncogenesis. 10:22021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lall SP, Alsafwani ZW, Batra SK and
Seshacharyulu P: ASPORIN: A root of the matter in tumors and their
host environment. Biochim Biophys Acta Rev Cancer. 1879:1890292024.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lim YC, Kang HJ and Moon JH: C-Met pathway
promotes self-renewal and tumorigenecity of head and neck squamous
cell carcinoma stem-like cell. Oral Oncol. 50:633–639. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rezakhani L, Salmani S, Eliyasi Dashtaki M
and Ghasemi S: Resveratrol: Targeting cancer stem cells and ncRNAs
to overcome cancer drug resistance. Curr Mol Med. 24:951–961. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kou N, Liu S, Li X, Li W, Zhong W, Gui L,
Chai S, Ren X, Na R, Zeng T and Liu H: H19 facilitates tongue
squamous cell carcinoma migration and invasion via sponging
miR-let-7. Oncol Res. 27:173–182. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wei J, Yang Y, Li Y, Mo X, Guo X, Zhang X,
Xu X, Jiang Z and You Q: Synthesis and evaluation of
N-(benzofuran-5-yl)aromaticsulfonamide derivatives as novel HIF-1
inhibitors that possess anti-angiogenic potential. Bioorg Med Chem.
25:1737–1746. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Condurat AL, Aminzadeh-Gohari S, Malnar M,
Schider N, Opitz L, Thomas R, Menon V, Kofler B and Pruszak J:
Verteporfin-induced proteotoxicity impairs cell homeostasis and
survival in neuroblastoma subtypes independent of YAP/TAZ
expression. Sci Rep. 13:37602023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jokela TA and LaBarge MA: Integration of
mechanical and ECM microenvironment signals in the determination of
cancer stem cell states. Curr Stem Cell Rep. 7:39–47. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ayob AZ and Ramasamy TS: Cancer stem cells
as key drivers of tumour progression. J Biomed Sci. 25:202018.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gurel C, Inetas G, Hortu I, Tunc E, Kuscu
GC, Dindaroglu FC, Sahin O, Buhur A and Oktem G: Cancer and cancer
stem cells: New molecular perspectives. Crit Rev Oncog. 24:99–104.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Atashzar MR, Baharlou R, Karami J,
Abdollahi H, Rezaei R, Pourramezan F and Zoljalali Moghaddam SH:
Cancer stem cells: A review from origin to therapeutic
implications. J Cell Physiol. 235:790–803. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dwivedi AR, Thakur A and Kumar V,
Skvortsova I and Kumar V: Targeting cancer stem cells pathways for
the effective treatment of cancer. Curr Drug Targets. 21:258–278.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lee MY, Giraddi RR and Tam WL: Cancer stem
cells: Concepts, challenges, and opportunities for cancer therapy.
Methods Mol Biol. 2005:43–66. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Galassi C, Esteller M, Vitale I and
Galluzzi L: Epigenetic control of immunoevasion in cancer stem
cells. Trends Cancer. 10:1052–1071. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang
X, Zhou Z, Shu G and Yin G: Wnt/β-catenin signalling: function,
biological mechanisms, and therapeutic opportunities. Signal
Transduct Target Ther. 7:32022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L, Wu
C, Wang C and Ye L: Wnt/β-catenin signaling in cancers and targeted
therapies. Signal Transduct Target Ther. 6:3072021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang X, Dong N and Hu X: Wnt/β-catenin
Signaling Inhibitors. Curr Top Med Chem. 23:880–896. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Cheng X, Xu X, Chen D, Zhao F and Wang W:
Therapeutic potential of targeting the Wnt/β-catenin signaling
pathway in colorectal cancer. Biomed Pharmacother. 110:473–481.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hayat R, Manzoor M and Hussain A: Wnt
signaling pathway: A comprehensive review. Cell Biol Int.
46:863–877. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Agaimy A and Haller F: CTNNB1
(β-catenin)-altered neoplasia: A review focusing on soft tissue
neoplasms and parenchymal lesions of uncertain histogenesis. Adv
Anat Pathol. 23:1–12. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Mccrea PD and Gottardi CJ: Beyond
β-catenin: Prospects for a larger catenin network in the nucleus.
Nat Rev Mol Cell Biol. 17:55–64. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Muhammad N, Bhattacharya S, Steele R,
Phillips N and Ray RB: Involvement of c-Fos in the promotion of
cancer stem-like cell properties in head and neck squamous cell
carcinoma. Clin Cancer Res. 23:3120–3128. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Reyes M, Flores T, Betancur D,
Peña-Oyarzún D and Torres VA: Wnt/β-catenin signaling in oral
carcinogenesis. Int J Mol Sci. 21:46822020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang Y and Wang X: Targeting the
Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol.
13:1652020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Safa AR: Resistance to cell death and its
modulation in cancer stem cells. Crit Rev Oncog. 21:203–219. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yan Q, Fang X, Li C, Lan P and Guan X:
Oncofetal proteins and cancer stem cells. Essays Biochem.
66:423–433. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wen X, Wu Y, Awadasseid A, Tanaka Y and
Zhang W: New advances in canonical Wnt/β-catenin signaling in
cancer. Cancer Manag Res. 12:6987–6998. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Ingham PW: Hedgehog signaling. Curr Top
Dev Biol. 149:1–58. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Smith AE, Sigurbjörnsdóttir ES,
Steingrímsson E and Sigurbjörnsdóttir S: Hedgehog signalling in
bone and osteoarthritis: The role of Smoothened and cholesterol.
FEBS J. 290:3059–3075. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Jiang J: Hedgehog signaling mechanism and
role in cancer. Semin Cancer Biol. 85:107–122. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Jia J and Jiang J: Regulation of
smoothened trafficking and abundance in hedgehog signaling. Front
Cell Dev Biol. 10:8478442022. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wu LF, Gao L, Hou XM, Zhang QH, Li S, Yang
YF and Lin XH: Drosophila miR-5 suppresses Hedgehog signaling by
directly targeting smoothened. FEBS Lett. 586:4052–4060. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Maier D: Membrane-anchored hairless
protein restrains notch signaling activity. Genes (Basel).
11:13152020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Salaritabar A, Berindan-Neagoe I, Darvish
B, Hadjiakhoondi F, Manayi A, Devi KP, Barreca D, Orhan IE, Süntar
I, Farooqi AA, et al: Targeting Hedgehog signaling pathway: Paving
the road for cancer therapy. Pharmacol Res. 141:466–480. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Shen D, Xia Y, Fu Y, Cao Q, Chen W, Zhu Y,
Guo K and Sun L: Hedgehog pathway and cancer: A new area (review).
Oncol Rep. 52:1162024. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Zhang Q and Jiang J: Regulation of
Hedgehog signal transduction by ubiquitination and
deubiquitination. Int J Mol Sci. 22:133382021. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Liu A: Proteostasis in the Hedgehog
signaling pathway. Semin Cell Dev Biol. 93:153–163. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Mohan M, Mannan A and Singh TG:
Therapeutic implication of Sonic Hedgehog as a potential modulator
in ischemic injury. Pharmacol Rep. 75:838–860. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Doheny D, Manore SG, Wong GL and Lo HW:
Hedgehog signaling and truncated GLI1 in cancer. Cells. 9:21142020.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Suchors C and Kim J: Canonical Hedgehog
pathway and noncanonical GLI transcription factor activation in
cancer. Cells. 11:25232022. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhang Y, Xie J, Wu H, Huang J, Zheng D,
Wang S, Jia X, He Z, Gong Y, Ju L and Sun Q: NK cell based
immunotherapy against oral squamous cell carcinoma. Front Immunol.
15:14407642024. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Raleigh DR and Reiter JF: Misactivation of
Hedgehog signaling causes inherited and sporadic cancers. J Clin
Invest. 129:465–475. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Zhang J, Fan J, Zeng X, Nie M, Luan J,
Wang Y, Ju D and Yin K: Hedgehog signaling in gastrointestinal
carcinogenesis and the gastrointestinal tumor microenvironment.
Acta Pharm Sin B. 11:609–620. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Sigafoos AN, Paradise BD and
Fernandez-Zapico ME: Hedgehog/GLI signaling pathway: Transduction,
regulation, and implications for disease. Cancers (Basel).
13:34102021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Koukourakis IM, Platoni K, Kouloulias V,
Arelaki S and Zygogianni A: Prostate cancer stem cells: Biology and
treatment implications. Int J Mol Sci. 24:148902023. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Izadpanah A, Mohammadkhani N, Masoudnia M,
Ghasemzad M, Saeedian A, Mehdizadeh H, Poorebrahim M and Ebrahimi
M: Update on immune-based therapy strategies targeting cancer stem
cells. Cancer Med. 12:18960–18980. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Köseer AS, Di Gaetano S, Arndt C, Bachmann
M and Dubrovska A: Immunotargeting of cancer stem cells. Cancers
(Basel). 15:16082023. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Hori K, Sen A and Artavanis-Tsakonas S:
Notch signaling at a glance. J Cell Sci. 126:2135–2140.
2013.PubMed/NCBI
|
|
77
|
Kopan R: Notch signaling. Cold Spring Harb
Perspect Biol. 4:a0112132012. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Wang H, Zang C, Liu XS and Aster JC: The
role of Notch receptors in transcriptional regulation. J Cell
Physiol. 230:982–988. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Shi Q, Xue C, Zeng Y, Yuan X, Chu Q, Jiang
S, Wang J, Zhang Y, Zhu D and Li L: Notch signaling pathway in
cancer: From mechanistic insights to targeted therapies. Signal
Transduct Target Ther. 9:1282024. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Zhou B, Lin W, Long Y, Yang Y, Zhang H, Wu
K and Chu Q: Notch signaling pathway: Architecture, disease, and
therapeutics. Signal Transduct Target Ther. 7:952022. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zanotti S and Canalis E: Notch signaling
and the skeleton. Endocr Rev. 37:223–253. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Vázquez-Ulloa E, Lin KL, Lizano M and
Sahlgren C: Reversible and bidirectional signaling of notch
ligands. Crit Rev Biochem Mol Biol. 57:377–398. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Paniri A, Hosseini MM, Amjadi-Moheb F,
Tabaripour R, Soleimani E, Langroudi MP, Zafari P and Akhavan-Niaki
H: The epigenetics orchestra of Notch signaling: A symphony for
cancer therapy. Epigenomics. 15:1337–1358. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Meurette O and Mehlen P: Notch signaling
in the tumor microenvironment. Cancer Cell. 34:536–548. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Bellavia D, Checquolo S, Palermo R and
Screpanti I: The Notch3 receptor and its intracellular
signaling-dependent oncogenic mechanisms. Adv Exp Med Biol.
1066:205–222. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Sun W, Gaykalova DA, Ochs MF, Mambo E,
Arnaoutakis D, Liu Y, Loyo M, Agrawal N, Howard J, Li R, et al:
Activation of the NOTCH pathway in head and neck cancer. Cancer
Res. 74:1091–1104. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Suarez RF, Sanlidag S and Sahlgren C:
Mechanical regulation of the Notch signaling pathway. Curr Opin
Cell Biol. 85:1022442023. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Ranj T: Upcoming market catalysts in Q4
2019. Nat Rev Drug Discov. 18:7382019. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Zheng Y, Wei K, Jiang P, Zhao J, Shan Y,
Shi Y, Zhao F, Chang C, Li Y, Zhou M, et al: Macrophage
polarization in rheumatoid arthritis: Signaling pathways, metabolic
reprogramming, and crosstalk with synovial fibroblasts. Front
Immunol. 15:13941082024. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Falo-Sanjuan J and Bray SJ: Decoding the
Notch signal. Dev Growth Differ. 62:4–14. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang
J, Zhang G, Wang X, Dong Z, Chen F and Cui H: Targeting cancer stem
cell pathways for cancer therapy. Signal Transduct Target Ther.
5:82020. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Espinoza I and Miele L: Deadly crosstalk:
Notch signaling at the intersection of EMT and cancer stem cells.
Cancer Lett. 341:41–45. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Zhu P and Fan Z: Cancer stem cells and
tumorigenesis. Biophys Rep. 4:178–188. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Xie J, Qi X, Wang Y, Yin X, Xu W, Han S,
Cai Y and Han W: Cancer-associated fibroblasts secrete
hypoxia-induced serglycin to promote head and neck squamous cell
carcinoma tumor cell growth in vitro and in vivo by activating the
Wnt/β-catenin pathway. Cell Oncol (Dordr). 44:661–671. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Djeungoue-Petga MA, Lurette O, Jean S,
Hamel-Côté G, Martín-Jiménez R, Bou M, Cannich A, Roy P and
Hebert-Chatelain E: Intramitochondrial Src kinase links
mitochondrial dysfunctions and aggressiveness of breast cancer
cells. Cell Death Dis. 10:9402019. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Garcia N, Al-Hendy A, Baracat EC, Carvalho
KC and Yang Q: Targeting hedgehog pathway and DNA
methyltransferases in uterine leiomyosarcoma cells. Cells.
10:532020. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Miyasaka A, Oda K, Ikeda Y, Sone K, Fukuda
T, Inaba K, Makii C, Enomoto A, Hosoya N, Tanikawa M, et al:
PI3K/mTOR pathway inhibition overcomes radioresistance via
suppression of the HIF1-α/VEGF pathway in endometrial cancer.
Gynecol Oncol. 138:174–180. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Xin Y, Jiang Q, Liu C and Qiu J: Plumbagin
has an inhibitory effect on the growth of TSCC PDX model and it
enhances the anticancer efficacy of cisplatin. Aging (Albany NY).
15:12225–12250. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Joshi P and Waghmare S: Molecular
signaling in cancer stem cells of tongue squamous cell carcinoma:
Therapeutic implications and challenges. World J Stem Cells.
15:438–452. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Antra Parashar P, Hungyo H, Jain A, Ahmad
S and Tandon V: Unraveling molecular mechanisms of head and neck
cancer. Crit Rev Oncol Hematol. 178:1037782022. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Soltaninezhad P, Mohtasham N, Arab F,
Sadeghi M, EbrahimZadeh N, Azghadi SF and Mohajertehran F:
Therapeutic potential of siRNAs in tongue squamous cell carcinoma
by modulating the PI3K/AKT and ERK signaling pathways: A systematic
review. Cell J. 26:337–350. 2024.PubMed/NCBI
|
|
102
|
Asl ER, Amini M, Najafi S, Mansoori B,
Mokhtarzadeh A, Mohammadi A, Lotfinejad P, Bagheri M, Shirjang S,
Lotfi Z, et al: Interplay between MAPK/ERK signaling pathway and
MicroRNAs: A crucial mechanism regulating cancer cell metabolism
and tumor progression. Life Sci. 278:1194992021. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Didonato JA, Mercurio F and Karin M: NF-κB
and the link between inflammation and cancer. Immunol Rev.
246:379–400. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Peng Y, Wang Y, Zhou C, Mei W and Zeng C:
PI3K/Akt/mTOR pathway and its role in cancer therapeutics: Are we
making headway? Front Oncol. 12:8191282022. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Rocamora-Blanch G, Climent F and Solanich
X: Histiocytosis. Med Clin (Barc). 161:166–175. 2023.(In English,
Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Zhang Y and Weinberg RA:
Epithelial-to-mesenchymal transition in cancer: Complexity and
opportunities. Front Med. 12:361–373. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Huang N, Sun X, Li P, Liu X, Zhang X, Chen
Q and Xin H: TRIM family contribute to tumorigenesis, cancer
development, and drug resistance. Exp Hematol Oncol. 11:752022.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Ang HL, Mohan CD, Shanmugam MK, Leong HC,
Makvandi P, Rangappa KS, Bishayee A, Kumar AP and Sethi G:
Mechanism of epithelial-mesenchymal transition in cancer and its
regulation by natural compounds. Med Res Rev. 43:1141–1200. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Saikia PJ, Pathak L, Mitra S and Das B:
The emerging role of oral microbiota in oral cancer initiation,
progression and stemness. Front Immunol. 14:11982692023. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Jin Y, Wang Z, He D, Zhu Y, Chen X and Cao
K: Identification of novel subtypes based on ssGSEA in
immune-related prognostic signature for tongue squamous cell
carcinoma. Cancer Med. 10:8693–8707. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Naponelli V, Rocchetti MT and Mangieri D:
Apigenin: Molecular mechanisms and therapeutic potential against
cancer spreading. Int J Mol Sci. 25:55692024. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Yadav AK and Desai NS: Cancer stem cells:
Acquisition, characteristics, therapeutic implications, targeting
strategies and future prospects. Stem Cell Rev Rep. 15:331–355.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Flaherty KT, Hodi FS and Fisher DE: From
genes to drugs: Targeted strategies for melanoma. Nat Rev Cancer.
12:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Freedman LP: On rigor and replication.
Science. 356:342017. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Kuşoğlu A and Biray Avcı Ç: Cancer stem
cells: A brief review of the current status. Gene. 681:80–85. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Zou B, Sun S, Qi X and Ji P: Aldehyde
dehydrogenase activity is a cancer stem cell marker of tongue
squamous cell carcinoma. Mol Med Rep. 5:1116–1120. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Chaudhury S, Panda S, Mohanty N, Panda S,
Mohapatra D, Nagaraja R, Sahoo A, Gopinath D, Lewkowicz N and
Lapinska B: Can immunoexpression of cancer stem cell markers
prognosticate tongue squamous cell carcinoma? A systematic review
and meta-analysis. J Clin Med. 12:27532023. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Yin J, Jiang Y, Wu H, Wang J, Zhang S and
Liu H: Overexpression of ZFX and its involvement in squamous cell
carcinoma of the tongue. Oncol Rep. 33:141–148. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Liu Z, He Q, Ding X, Zhao T, Zhao L and
Wang A: SOD2 is a C-myc target gene that promotes the migration and
invasion of tongue squamous cell carcinoma involving cancer
stem-like cells. Int J Biochem Cell Biol. 60:139–146. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Varnat F, Siegl-Cachedenier I, Malerba M,
Gervaz P and Ruiz i Altaba A: Loss of WNT-TCF addiction and
enhancement of HH-GLI1 signalling define the metastatic transition
of human colon carcinomas. EMBO Mol Med. 2:440–457. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Lee J, Kim E, Chong K, Ryu SW, Kim C, Choi
K, Kim JH and Choi C: Atypical induction of HIF-1α expression by
pericellular Notch1 signaling suffices for the malignancy of
glioblastoma multiforme cells. Cell Mol Life Sci. 79:5372022.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Wu Y, Wan XW, Jiang L, Wang W, Zhu JJ and
Shao YS: Rhaponitin reverses cisplatin resistance and impairs
cancer stemness through HIF-1α/MCT4/Wnt pathway in tongue squamous
cell carcinoma. Kaohsiung J Med Sci. 41:e700692025. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Anglès F, Gupta V, Wang C and Balch WE:
COPII cage assembly factor Sec13 integrates information flow
regulating endomembrane function in response to human variation.
Sci Rep. 14:101602024. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Wang J, Li L, Gao L, Guan C, Su K, Li L,
Luo W, Chen H and Ji P: Identification of differentially expressed
genes in oral squamous cell carcinoma TCA8113 cells. Oncol Lett.
14:7055–7068. 2017.PubMed/NCBI
|
|
125
|
Li Y, Wang Z, Ajani JA and Song S: Drug
resistance and cancer stem cells. Cell Commun Signal. 19:192021.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Chinn LK, Ovchinnikova I, Sukmanova AA,
Davydova AO and Grigorenko EL: Early institutionalized care
disrupts the development of emotion processing in prosody. Dev
Psychopathol. 33:421–430. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Yang J, Ji P, Zou B, Sun S and Qi X:
Biological characteristics of cells expressing high level of
aldehyde dehydrogenase subpopulation in tongue squamous cell
carcinoma Tca8113 cell line. Hua Xi Kou Qiang Yi Xue Za Zhi.
30:439–443. 2012.(In Chinese). PubMed/NCBI
|
|
128
|
Sun X, Lv X, Yan Y, Zhao Y, Ma R, He M and
Wei M: Hypoxia-mediated cancer stem cell resistance and targeted
therapy. Biomed Pharmacother. 130:1106232020. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Najafi M, Farhood B, Mortezaee K,
Kharazinejad E, Majidpoor J and Ahadi R: Hypoxia in solid tumors: A
key promoter of cancer stem cell (CSC) resistance. J Cancer Res
Clin Oncol. 146:19–31. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Zeng Z, Fu M, Hu Y, Wei Y, Wei X and Luo
M: Regulation and signaling pathways in cancer stem cells:
Implications for targeted therapy for cancer. Mol Cancer.
22:1722023. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Zhou M, Niu H, Cui D, Xu M, Li J, Huang G,
Zhou M, Xiong C, Liu Y, Xu X, et al: Cancer stem cell-driven drug
resistance in colorectal carcinoma: Molecular aspects and
therapeutic potentials. Mol Cancer. 25:542026. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
No authors listed. Deutsche
pharmakologische gesellschaft. Abstracts. 27th spring meeting,
March 11–14, 1986, Mainz. Naunyn Schmiedebergs Arch Pharmacol. 332
(Suppl):R1–R104. 1986.
|
|
133
|
Najafi M, Farhood B and Mortezaee K:
Cancer stem cells (CSCs) in cancer progression and therapy. J Cell
Physiol. 234:8381–8395. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Lathia J, Liu H and Matei D: The clinical
impact of cancer stem cells. Oncologist. 25:123–131. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Zhou H, Tan L, Liu B and Guan XY: Cancer
stem cells: Recent insights and therapies. Biochem Pharmacol.
209:1154412023. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Huang B, Yan X and Li Y: Cancer stem cell
for tumor therapy. Cancers (Basel). 13:48142021. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Akbar Samadani A, Keymoradzdeh A, Shams S,
Soleymanpour A, Elham Norollahi S, Vahidi S, Rashidy-Pour A, Ashraf
A, Mirzajani E, Khanaki K, et al: Mechanisms of cancer stem cell
therapy. Clin Chim Acta. 510:581–592. 2020. View Article : Google Scholar : PubMed/NCBI
|
